CytoDyn Submits the First of Three Main Sections of HIV BLA to FDA Under Previously Authorized Rolling Review

by NASDAQ Market News November 16, 2021

NASDAQ Market News
Click here to email author

Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts

NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results

Ads